Causes and Natural History of Dyslipidemias
This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to conditions like ather
| Condition(s) | Hypercholesterolemia, Atherosclerosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to conditions like atherosclerosis (hardening of the arteries) or heart attack. Participants will undergo accepted medical tests and procedures to evaluate their condition. Most of the test results are helpful in making a diagnosis and in guiding treatment. People with lipid disorders are eligible for this study. Representative types of patients include those with: * Plasma cholesterol levels greater than 200 mg/dl or less than 120 mg/dl * Plasma LDL-C levels greater than 130 mg/dl or less than 70 m |
| Who can participate | * INCLUSION CRITERIA: * Children \>= 2 years of age and \>12 kg and adults * Dyslipidemia subjects of interest the group The following is a representative list of the types of patient presentations with dyslipidemia and potential diagnoses eligible for this protocol: * Plasma cholesterol levels \>200 mg/dl or \<120 mg/dl includes patients with diagnoses such as familial hypercholesterolemia, familial combined hyperlipidemia, sitosterolemia, lipoprotein lipase, hepatic lipase or apo-CII deficiency, and dysbetalipoproteinemia. * Plasma LDL-C levels \>130 mg/dl or \<70 mg/dl includes patients with diagnoses such as familial hypercholesterolemia, PCSK9, apo3500, familial combined hyperlipidemia, sitosterolemia, dysbetalipoproteinemia, abetalipoproteinemia and hypobetalipoproteinemia. * Plasma |
| Ages | 2 Years to 100 Years |
| Sex | All |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Locations | Bethesda, Maryland, United States |
| Start date | 2003-10-14 |
| NCT ID | NCT00353782 |
| Official listing | https://clinicaltrials.gov/study/NCT00353782 |